Great opportunity with our Finance team!
Come join our team! Check out this job at Xencor: Associate Director, Financial Planning & Analysis
About us
Proteins by Design Antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. At Xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life. Our XmAb antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. This combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. The XmAb® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by Xencor and by pharmaceutical partners. Xencor is also discovering biologics products that improve the performance of old antibody drugs, known as biosuperiors, to benefit patients, ease compliance and help reduce costs.
- Website
-
http://www.xencor.com
External link for Xencor
- Industry
- Biotechnology
- Company size
- 201-500 employees
- Headquarters
- Pasadena, California
- Type
- Public Company
- Founded
- 1997
- Specialties
- Protein engineering, Drug development, Antibody drugs, Biotechnology, Oncology, Autoimmune disease, Bispecific antibodies, and Cytokines
Locations
-
Primary
Get directions
465 N Halstead St
Suite 200
Pasadena, California 91107, US
-
Get directions
12770 High Bluff Drive Unit 260
San Diego, CA 92130-2077, US
Employees at Xencor
Updates
-
Xencor kicked off the #LABEST2024 Pasadena Ecosystem Tour, with CEO Bassil Dahiyat leading a tour of our state-of-the-art protein engineering laboratories for attendees. LABEST, the LA Bioscience Ecosystem Summit, is the premier showcase for bioscience innovation in Los Angeles County. Follow the link to learn more about the event, produced by UCLA Technology Development Group. https://lnkd.in/gpUQDvMK
-
-
We're #hiring a new Director, Pharmacovigilance in San Diego, California. Apply today or share this post with your network.
-
We're #hiring a new Analyst, Corporate Strategy in Pasadena, California. Apply today or share this post with your network.
-
We're #hiring a new Executive Director, Information Technology in Pasadena, California. Apply today or share this post with your network.
-
We're #hiring a new Contract-Facilities Technician in Pasadena, California. Apply today or share this post with your network.
-
Our Senior Director, Protein Engineering Gregory Moore gave a presentation entitled "Modulating the immune system with CD28 costimulatory bispecific antibodies” at the Festival of Biologics in San Diego and discussed this novel approach to utilize bispecific T cell engagers for the potential treatment of patients with multiple solid tumor types. Click the link for more information on our clinical pipeline, including our leading tumor-selective costimulating bispecific antibody, XmAb808. #festivalofbiologics #proteinengineering #bispecificantibodies
-
Today we welcome Bart Cornelissen as our senior vice president & chief financial officer. Bart has more than 20 years of experience in corporate financial planning, analysis and transactions, and he was most recently vice president, corporate finance at Seagen Inc., where he built and scaled the corporate finance organization to support tremendous revenue growth and dealmaking activity. Read more here: https://lnkd.in/g33-J9rK
Xencor Appoints Bart Cornelissen as Chief Financial Officer | Xencor, Inc.
investors.xencor.com
-
“Xencor is focused on advancing our high-potential XmAb CD3 and CD28 T-cell engagers for the treatment of patients with solid tumors and the evaluation of our PD-1 x CTLA-4 dual checkpoint inhibitor, vudalimab.” - Bassil Dahiyat Read more in our recent business and clinical highlights press release: https://lnkd.in/gca99eMk #biotechnology #bispecificantibodies #earnings
Xencor Reports Fourth Quarter and Full Year 2023 Financial Results | Xencor, Inc.
investors.xencor.com
-
ICYMI: Brad Loncar from BiotechTV visited our Pasadena labs to interview Xencor President and CEO Bassil Dahiyat. Follow the link to tune into their conversation about the latest advances in bispecific antibody engineering, key targets of interest to put on your radar, and the growing biotech scene in LA. #proteinengineering #bispecificantibodies #LAbiotech https://lnkd.in/g-mbGFE5
Five Questions with Xencor CEO Bassil Dahiyat
biotechtv.com